Cerylana

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Cerylana

Quick Facts

Property Description
Active ingredient Diphenhydramine hydrochloride
Form Tablet, capsule, oral solution, injection
Pharmacological class First-generation H1-Antihistamine
Common purpose Relief of allergy symptoms, sedation, antiemetic
Origin Synthetic compound

What Type of Medicine is Cerylana?

Cerylana is a medicinal preparation classified primarily as a first-generation antihistamine, with its therapeutic effects derived from the single active component, Diphenhydramine. This synthetic compound functions as an H1-receptor antagonist, meaning its core action is to block the effects of histamine throughout the body. Its defining feature is its classification as a first-generation agent, a characteristic clinically recognized for its ability to readily cross the blood-brain barrier. This structural property significantly differentiates it from newer, second-generation antihistamines, which are specifically designed to minimize central nervous system penetration.

Composition and Common Preparations

The composition of Cerylana centers exclusively on the Diphenhydramine molecule, typically formulated as its stable hydrochloride salt, integrated with standard pharmaceutical excipients necessary for stability and absorption. As a systemic medication, Cerylana is manufactured for various routes of administration, most commonly presented for oral use as a tablet, capsule, or oral solution. Injectable parenteral preparations are also manufactured to ensure the active ingredient can be delivered efficiently in specific clinical contexts.

The General Purpose of Cerylana

The primary general purpose of Cerylana is the palliative relief of acute symptoms associated with allergic reactions, which are triggered by the body’s release of histamine. Beyond its anti-allergy function, the medication’s unique influence on the central nervous system affords it secondary utility. The medication possesses dual utility as both an effective antihistamine and a sleep-promoting agent. Consequently, a typical use scenario involves its application for temporary relief when a person experiences both allergy symptoms and related difficulty sleeping. Furthermore, its recognized anticholinergic properties contribute to its application in managing symptoms related to motion sickness, establishing its broad, multifaceted therapeutic profile.

Regulatory References

  1. NIH MedlinePlus

What side effects are possible with Cerylana?

Possible Side Effects and Safety Information

The safety profile of Cerylana, containing Diphenhydramine, is officially defined by effects related to its classification as a first-generation antihistamine. Regulatory documents organize adverse reactions primarily across several physiological systems and by their documented frequency.

Documented Adverse Reactions

The most frequently observed adverse reactions are categorized as Common, including drowsiness and dry mouth. Effects such as constipation, diarrhea, nausea, and urinary retention are classified as Uncommon. Many other reactions, such as confusion, tremor, blurred vision, hypotension, and palpitations, are listed as having an Unknown Frequency in regulatory summaries.

Adverse reactions are grouped by System-Organ Class (SOC) and commonly involve the Nervous System (sedation, dizziness, disturbed coordination) and the Gastrointestinal System (dry mouth, epigastric distress, vomiting).

Serious Safety Considerations

The official labeling documents rare but serious adverse reactions, which include reports of anaphylactic shock and specific hematologic disorders such as hemolytic anemia and agranulocytosis. Convulsions are also documented as a serious adverse reaction. Warnings specifically highlight the risk of serious heart problems and death associated with taking high doses.

Population-Specific Constraints

Safety notes define specific constraints for certain populations. The medicine is contraindicated in neonates and premature infants. Pediatric patients may, paradoxically, experience excitation or restlessness. Older adults (approximately 60 years and older) are officially noted to be more susceptible to adverse effects such as dizziness, sedation, and hypotension.

Regulatory information also dictates that Cerylana impairs mental and physical abilities required for operating machinery or driving, which is a mandatory safety restriction in official labeling.

Overdose and Emergency Response

Cerylana Overdose and when to seek help

Overdosage with Cerylana presents with documented manifestations ranging from severe central nervous system (CNS) depression, including profound sedation and coma, to CNS stimulation, which may involve restlessness, confusion, tremor, and hallucinations. Regulatory documents emphasize that overdosage can lead to life-threatening outcomes, specifically highlighting the risk of convulsions (seizures), respiratory failure, and serious cardiac conduction abnormalities such as QRS widening and potentially fatal arrhythmias.

When Immediate Medical Help is Required

Official governmental guidance requires that emergency medical attention be sought immediately if a person exhibits severe symptoms such as a seizure, trouble breathing, collapse, or if they are hallucinating or cannot be awakened. Contacting emergency services or Poison Control is mandated under these specific clinical circumstances.

Management and Special Considerations

The prescribed regulatory approach for managing Cerylana overdosage is symptomatic and supportive treatment. Official labeling states that no specific antidote is known, and it specifies that stimulants should not be administered. Furthermore, continuous cardiac monitoring is documented as a requirement. Regulatory information also notes that severe CNS stimulation is particularly likely in pediatric patients, while elderly patients are more susceptible to severe dizziness, sedation, and hypotension.

Therapeutic Uses of Cerylana

Cerylana is applied across domains where additional symptomatic support is needed, primarily focusing on conditions involving episodic or fluctuating manifestations and symptoms that create noticeable physiological strain. The medication is commonly used to help with a range of acute, distressing symptoms, providing supportive relief when physical discomfort interferes with daily stability.

The medication helps address symptom clusters that may become intense or disruptive due to inflammatory or irritative states. It is relevant for easing challenging symptoms like persistent sneezing, a runny nose, and the pronounced itching of the eyes, throat, and skin, and is used for managing the vestibular and gastrointestinal symptoms associated with motion sickness. Furthermore, it is commonly used across conditions presenting with acute episodes of sleeplessness.

The general benefit provided is symptomatic relief that helps patients cope more steadily with symptom fluctuations. It supports the patient during difficult episodes by easing distress and is applied in clinical settings for situations requiring temporary assistance, such as addressing symptoms related to organ-specific functional stress.

“It is relevant for easing challenging symptoms like persistent sneezing, a runny nose, and the pronounced itching of the eyes, throat, and skin.”

Quick Fact: Relief for Acute Symptoms
Primary Focus Allergic symptoms, temporary insomnia, motion sickness
Patient Benefit Contributes to improved comfort during periods of heightened symptoms
Symptom Type Episodic, disruptive, and inflammatory manifestations

Regulatory References

  1. NIH MedlinePlus overview

Eligibility and Restrictions for Use

Official Population Eligibility for Cerylana (Diphenhydramine)

Cerylana’s eligibility profile is strictly defined by regulatory authorities based on population age and pre-existing physiological states or conditions.

Eligibility Status Applicable Population / Condition
Contraindicated (Prohibited Use) Neonates or premature infants; Nursing mothers; Patients with a known hypersensitivity to the active ingredient.
Conditional Use Only Pregnancy (FDA Category B). Use is permitted only if clearly needed.
Restricted or Caution Required Older adults (60 years or older) are a high-risk population where use is generally not recommended. Children under 2 years should avoid non-prescription cold/cough use.

Official eligibility statements:

  • The medicine must be used with considerable caution in patients with conditions sensitive to its effects, including narrow-angle glaucoma, stenosing peptic ulcer, or symptomatic prostatic hypertrophy.
  • Contraindication in nursing mothers is based on the elevated risk for infants, particularly neonates.

The regulatory documents establish who may use the medicine through a framework of absolute prohibitions for certain age groups and physiological states, coupled with cautions and restrictions for individuals with specific comorbidities sensitive to the drug’s properties.

What should I know about interactions with other medicines?

Interactions with Other Medicines and Products

Official regulatory documents define specific substances and substance classes that have documented interaction patterns with Cerylana (Diphenhydramine hydrochloride).


Documented Interaction Restrictions

Restriction Type Interacting Substance(s) Official Regulatory Statement
Contraindicated Combination Monoamine Oxidase Inhibitors (MAOIs) Prohibited for co-administration or within 14 days of stopping MAOI treatment.
Prohibited Co-administration Other products containing Diphenhydramine Not to be used concurrently due to the risk of overexposure.
Exposure Modification Risk CYP2D6 Inhibitors, Metoprolol, Venlafaxine Use with caution or avoid; Cerylana is a CYP2D6 inhibitor and substrate, potentially increasing plasma levels of co-administered drugs like Metoprolol and Venlafaxine.

Pharmacodynamic and Substance Interactions

The primary interaction mechanism documented is pharmacodynamic reinforcement.

Interacting Class Resulting Interaction Pattern
CNS Depressants (e.g., Sedatives, Opioids) Results in additive CNS depression, enhancing sedative effects.
Anticholinergic Drugs (e.g., Tricyclic Antidepressants) Potentiates and intensifies anticholinergic effects, such as dry mouth.
Alcohol Explicitly documented to significantly enhance the effects of Cerylana, intensifying CNS depression.

Cautionary notes also apply to populations with hepatic or renal dysfunction, where altered clearance may impact the consequences of co-administration. These restrictions and classifications are based strictly on regulatory prescribing information.

Mechanism of Action

How Cerylana Works

Cerylana's core mechanism involves its function as a competitive antagonist at the Histamine H1-receptor throughout the body. By blocking this receptor, the molecule prevents the binding of endogenous histamine, which in turn decreases the histamine-mediated increase in capillary permeability and fluid extravasation into tissues.

Due to the drug's lipophilic structure, it easily penetrates the Blood-Brain Barrier to engage H1 receptors in the Central Nervous System. This central blockade suppresses the histaminergic neurons active in CNS arousal circuits, contributing to CNS depression and a decrease in central histamine-driven activity.

The molecule also exhibits affinity for Muscarinic cholinergic receptors, acting as an antagonist in both central and peripheral pathways. This anticholinergic mechanism alters the signaling within pathways that control involuntary reflexes and secretions, specifically modulating inputs to the emetic center which regulates the vomiting reflex.

Dosage and Administration Information

How Cerylana is Used: Official Administration Guidelines

Cerylana (Diphenhydramine hydrochloride) must be administered according to specific, standardized instructions outlined in regulatory labeling, which dictate the correct route, dosage, and frequency of use.

Approved Administration Routes and Forms: Cerylana is approved for systemic delivery via Oral route (tablet, capsule, or solution) and Parenteral route as an injection for Intramuscular (IM) or Intravenous (IV) use. The parenteral form is indicated only when the oral route is impractical.

Administration Route Standard Adult Dose Frequency and Maximum (24hr)
Oral (Symptom Relief) 25 mg to 50 mg Every 4 to 6 hours, Max: 300 mg
Oral (Sleep Aid) 50 mg Once at bedtime
Parenteral (IM/IV) 10 mg to 50 mg Every 4 to 6 hours, Max: 400 mg

Key Administration Conditions:

  • Timing: The oral dose may be administered without regard to meals. For motion sickness prophylaxis, the first dose is recommended 30 minutes prior to travel.
  • IV Rate: Intravenous administration must be controlled; the rate of injection should generally not exceed 25 mg/minute.
  • Special Populations: Official guidance advises using the lowest effective dose for older adults, and a lower initial dose is considered advisable. Pediatric dosing for parenteral use is based on weight or surface area (5 mg/kg/24 hours or 150 mg/m^2/ 24 hours) divided into four doses, with use contraindicated in neonates and premature infants.

These official instructions standardize the use of Cerylana by establishing precise mg limits, defining the appropriate time intervals between doses, and mandating specific procedures for injectable administration.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Cerylana

Evidence for Acute Allergic Symptoms

Research has extensively examined the role of the active ingredient in Cerylana (Diphenhydramine) in managing conditions characterized by fluctuating or episodic manifestations, such as allergic rhinitis (hay fever) and acute urticaria (hives). Studies primarily include short-term Randomized Controlled Trials (RCTs) and systematic reviews. These studies were used in research exploring how symptoms change over time and typically measured outcomes related to inflammatory or irritative states, such as sneezing, nasal discharge, itching, and the suppression of allergic skin reactions.

The findings describe patterns observed in the studies where the agent was studied for its ability to observe patterns during episodes where symptoms become more noticeable. Research also explored the measurement of changes that were observed. While a substantial body of research exists, there is limited information for long-term outcomes regarding the agent's role in the maintenance or chronic management of these conditions.

Evidence for Temporary Relief of Sleeplessness

The agent was evaluated in research contexts involving temporary difficulty sleeping. Studies primarily relied on RCTs and meta-analyses that specifically monitored outcomes such as the time it took participants to fall asleep and the total duration of sleep. To assess the aftereffects, researchers also examined objective tests of outcomes reflecting daily functioning or activity level the morning after administration. The research was typically conducted during periods of increased symptom activity (sleeplessness) in otherwise healthy adult populations.

The data show patterns related to sleep latency following acute, single-dose use. However, evidence also suggests that these patterns may diminish when the agent is observed in repeated use over a short period (e.g., 1–2 weeks), as the body appears to develop tolerance. Long-term effects are not fully established regarding the use of this agent as a regular sleep aid.

Key Research Gaps and Uncertainties

Long-term effects are not fully established for any of the primary indications, and there is limited information regarding functional outcomes beyond immediate symptom changes. Evidence quality varies across studies, particularly for certain uses like temporary sleep aid. Subgroup findings are uncertain in many areas, meaning the results apply only to the populations studied and research does not determine whether an individual will respond similarly outside those specific trial conditions. The findings help contextualize how patients reported their experience in the short term, but certainty remains low for long-term predictability.

Key Studies & References

  1. DIPHENHYDRAMINE HYDROCHLORIDE capsule Drug Label

Frequently Asked Questions (FAQ)

Common questions about Cerylana (FAQ)


Q: Is it normal to have headaches when first starting Cerylana?

Regulatory documents list headache as a documented adverse reaction, which is classified under effects related to the Nervous System. The official labeling does not specify whether this symptom is reported to occur predominantly during the initial period of use.


Q: Does Cerylana interact with common over-the-counter pain relievers?

Official sources caution that Cerylana should be used carefully with other medicines that may cause drowsiness or dry mouth, which includes certain classes of over-the-counter pain relievers. Some non-prescription products, particularly those containing other sedating ingredients or opioids, can increase the sedative effects of Cerylana. General pain relievers such as non-steroidal anti-inflammatory drugs (NSAIDs) or acetaminophen are not named as specific prohibited interactions in standard U.S. regulatory documents.


Q: How quickly can someone expect to see a response after starting Cerylana?

The injectable form of Cerylana is described in official documentation as having a rapid onset of action. For the oral forms, a precise timeframe for the onset of effects is not specified in most regulatory summaries. The intended effects for the oral forms typically begin after the active ingredient is absorbed.


Q: How long is Cerylana typically taken for according to the studies?

Regulatory guidelines and research overviews describe Cerylana’s use for the temporary relief of acute symptoms, such as occasional sleeplessness and allergic reactions. Research studies for these purposes are often short-term, and official documents note that there is limited data to characterize outcomes or safety for chronic, long-term use.


Q: Are there any long-term side effects associated with Cerylana use?

Official labeling states that long-term studies in animals to determine carcinogenic or mutagenic potential have not been performed. Official documents state that long-term safety data in humans for chronic use are limited, as the medicine is intended for short-term symptom relief.


Q: Can Cerylana affect my sleep schedule or cause insomnia?

Official documentation notes that while Cerylana is used as an aid for occasional sleeplessness due to its sedative effect, it can sometimes have paradoxical effects. The list of documented adverse reactions includes both sedation and, in some cases, insomnia, excitation, or restlessness.


Q: Is Cerylana used for conditions other than the one listed in the official documents?

Official regulatory documents define the approved uses for Cerylana, which include the relief of allergic reactions, motion sickness, and certain cases of parkinsonism. Use for any condition that is not listed in the Indications and Usage section of the official labeling is considered outside of the intended use.


Q: Do I need to change my diet while taking Cerylana?

Official regulatory documents indicate that the oral dose of Cerylana is to be administered without regard to meals. There are no general requirements in the regulatory information to alter one's diet while using the medicine.


Q: Does Cerylana make you feel tired or dizzy?

Yes. According to official product documentation, drowsiness (sedation) and dizziness are identified as among the most frequently observed adverse reactions. Patients are officially warned that Cerylana may impair mental and physical abilities required for driving or operating machinery.


Q: How does Cerylana impact the liver or kidneys?

Regulatory documents state that Cerylana is metabolized primarily in the liver and excreted by the kidneys. Official labeling notes that altered clearance of the drug may occur in populations with pre-existing hepatic or renal dysfunction. Its anticholinergic properties can also contribute to issues like urinary retention.


Q: Can Cerylana affect a drug test?

Cerylana's active ingredient, diphenhydramine, may potentially cause a false-positive result for certain substance classes, such as opioids or methadone, on some preliminary drug screening tests. Preliminary drug screening tests may detect the active ingredient, diphenhydramine. This may potentially lead to a false-positive result for certain substance classes, such as opioids or methadone.


Q: What happens if I accidentally miss a dose of Cerylana?

Official drug information usually describes a standard procedure that involves taking the missed dose as soon as it is remembered, unless it is nearly time for the next scheduled dose. Regulatory sources caution against taking two doses at once to avoid risks associated with overdose.


Q: Are there any specific foods or supplements to avoid when taking Cerylana?

Official documents explicitly warn against the concurrent use of alcohol due to the enhanced effect of central nervous system depression. No specific foods are listed as mandatory prohibitions, but caution is advised with herbal supplements that have sedative or anticholinergic properties, as these effects could be intensified.


Q: Is Cerylana safe to take with birth control pills?

Standard regulatory labels do not typically list a specific interaction between Cerylana and common hormonal contraceptives. However, Cerylana can interact with the CYP2D6 enzyme, which may theoretically impact the metabolism of other co-administered drugs.


Q: Is there a generic version of Cerylana available?

Yes, there is. The active ingredient in Cerylana, Diphenhydramine hydrochloride, is available in numerous generic and non-prescription formulations. These generic versions are considered equivalent to the brand-name product.


Q: What should I do if I think I'm experiencing a side effect from Cerylana?

Official documents describe that experiencing a serious adverse reaction is an event that requires immediate medical help. The labeling also defines the process for reporting suspected adverse reactions to the relevant government health authority (e.g., FDA MedWatch).


Q: What are some common user experiences reported with Cerylana?

The most frequent adverse reactions documented in regulatory sources, which align with common reported experiences, include drowsiness, dry mouth, and potential issues such as constipation or disturbed coordination. These are effects that are known to occur due to the medicine's primary mode of action.


Q: Does Cerylana interact with herbal supplements like St. John's Wort?

Regulatory warnings focus on the additive effects of Cerylana with other substances. Caution is generally advised with herbal remedies or supplements that possess sedative or anticholinergic properties, as combining these could intensify the effects of Cerylana.


Q: What happens if I take Cerylana for longer than the recommended time?

Regulatory guidance cautions against taking more than the maximum daily dose or using it for an extended period, as it is intended for short-term use. Extended or high-dose use increases the risk of serious adverse effects, including overdose, serious heart problems, or potentially death, according to regulatory warnings.


Q: Is there an established maximum duration for taking Cerylana?

For its common non-prescription uses, Cerylana is intended for short-term relief of symptoms, typically specified as mathbf7 days for allergy symptoms or as a temporary sleep aid. Official regulatory warnings describe the risks associated with exceeding the maximum daily dose or using the medicine beyond the temporary period.


Q: Can I crush or split the Cerylana pill?

Official instructions for chewable tablet formulations require that the tablets be chewed or crushed completely before swallowing. However, this instruction is specific to that form and may not apply to all tablet or capsule formulations. The official documentation for the specific product form would contain the correct administration instruction.


Q: Why do some people report stomach issues when they start Cerylana?

Official documentation lists several gastrointestinal adverse reactions that are known to occur during use, including epigastric distress, nausea, vomiting, diarrhea, and constipation. These issues are possible at any point during use, including when starting the medicine, as they are related to its systemic effects.


Q: What is the half-life of Cerylana in the body?

Official pharmacokinetic data indicates that the half-life of Cerylana's active ingredient, Diphenhydramine, typically ranges between approximately mathbf5 to mathbf8 hours in healthy adults. This figure helps describe the rate at which the drug leaves the body.


Q: How does Cerylana interact with common heart medications?

Official regulatory warnings advise that Cerylana should be used with caution in individuals with a history of cardiovascular disease or hypertension (high blood pressure). Adverse effects like palpitations (fast heart rate) and hypotension (low blood pressure) are documented, suggesting a potential for risk or interaction with heart-regulating medicines.


Q: Is there a link between Cerylana and vision changes?

Yes. Official warnings and adverse reaction lists include potential effects on the eyes such as blurred vision. More serious visual effects, like sudden eye pain, are also possible, particularly in patients with pre-existing conditions sensitive to the drug’s anticholinergic properties (such as glaucoma).


Q: Why is Cerylana sometimes referred to by a different, chemical name?

Cerylana is the brand name used for marketing and prescribing. The active ingredient itself is Diphenhydramine hydrochloride. It may also be referred to by its full chemical name (e.g., 2-benzhydryloxy-N,N-dimethylethanamine) in highly technical or scientific documentation, as this name describes the molecule’s exact structure.


Q: Does Cerylana require a prescription from a doctor?

In many regions, formulations of Cerylana’s active ingredient are approved and widely available for non-prescription (Over-the-Counter or OTC) use for certain indications, such as allergy relief and temporary sleep aid. However, specialized preparations, such as the injectable form or high-strength tablets, typically require a prescription.


Q: Can I take Cerylana if I have a history of high blood pressure?

Official regulatory warnings advise that Cerylana should be used with caution in patients who have a history of hypertension (high blood pressure) or other cardiovascular disease. This is due to the documented potential for effects like hypotension (low blood pressure) and tachycardia (fast heart rate) to occur.

How should Cerylana be stored and disposed of?

How to Store and Dispose of Cerylana

The official labeling for Cerylana (Diphenhydramine Hydrochloride) mandates specific environmental controls to maintain product stability and safety. The medication must be stored at Controlled Room Temperature, 20° to 25°C (68° to 77°F).

Storage Requirements

Condition Regulatory Requirement
Temperature Restriction Must be Protected from freezing and generally should not be refrigerated.
Light Protection The product must be Protected from light and stored in a tightly closed container.
Child Safety The medicine must be stored out of the sight and reach of children.

Disposal

Disposal instructions require that all unused or expired Cerylana product be handled in accordance with local regulations. This instruction prevents the product from entering the wastewater system or general household trash.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Cerylana found in:

A-Z Index: